As biotech has gone from strength to strength over the past four decades, China has been a backwater for the industry, tending to follow the west rather than pursuing its own innovations. The Chinese companies are determined to become leaders in this. These treatments have the potential to be highly disruptive to medicine and I think they view it as a unique opportunity as new contenders to spring to the forefront of the biotech industry. （Healthcare: Cancer breakthrough leads China's biotech boom, by Financial Times）
Comment
In recent years, China's innovation power has been reflected by the booming of biotech in its market. IPR protection in turn serves a strong underpinner for the upgrading of such technology.
（Editor Li Xingyi）
（All contents of this newspaper may not be reproduced or used without express permission）